High-throughput screening of clinically approved drugs that prime nonviral gene delivery to human Mesenchymal stem cells

Table 2 Lowest fold-changes in transfection priming hits in each donor

	Drug	Drug Class	Concentration [μM]	TE^a	EGFP^b	RLU/mg^c	Viability^d	Hoechst^e
Donor 1	Homoharringtonine	Antineoplastic	100	3.0	5.4	70	0.6	0.5
	Epigallocatechin gallate	Flavonoid	100	8.3	4.1	57	1.3	2.0
	Desipramine hydrochloride	Antidepressant	100	1.6	6.3	58	0.8	0.3
	Rifapentine	Antibiotic	100	8.8	5.0	15	1.1	1.7
	Hexachlorophene	Antiseptic	100	6.9	4.2	5.5	1.0	1.6
Donor 2	Epigallocatechin gallate	Flavonoid	100	42	32	25	1.1	1.4
	Lomerizine dihydrochloride	Antihypertensive	100	7.9	7.3	17	0.7	1.0
	Meclizine hydrochloride	Antihistamine	100	2.6	2.5	17	0.9	1.1
	Docetaxel	Antineoplastic	13	1.9	2.6	9.2	1.0	0.6
	Rifapentine	Antibiotic	100	5.7	3.4	3.5	1.0	1.7

^aTE FCs were calculated from triplicate averages of EGFP positive cell-counts normalized to Hoechst-counts, relative to the same measurement averaged from the VCs in each compound’s respective plate
^bGFP FCs were calculated from triplicate averages of EGFP positive cell-counts, relative to the same measurement averaged from the VCs in each compound’s respective plate
^cRLU/mg FCs were calculated from triplicate averages of luciferase luminescence, in relative light units (RLUs), normalized to total protein, relative to the same measurement averaged from the VCs in each compound’s respective plate
^dViability ratios were calculated from triplicate averages of live cell-counts (number of Hoechst stained objects minus number of ethidium stained objects) normalized to Hoechst-counts, relative to the same measurement averaged from the VCs in each compound’s respective plate
^eHoechst ratios were calculated from triplicate averages of total cell-count (determined by Hoechst-count), relative to the same measurement averaged from the VCs in each compound’s respective plate

ISSN: 1754-1611